Spiropiperidylrifamycins for the treatment of mycobacterial infections
US7521458B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 4, 2005 |
| Grant date | Apr 21, 2009 |
| Priority date | — |
| Expiry date | Aug 10, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The compounds of formula (1), their pharmaceutically acceptable salts and their solvates, wherein R1 is a radical selected between hydrogen and alkyl; R2 is selected from hydroxyalkyl, phenyl, phenyl mono-substituted and phenyl di-substituted in positions 3 and 4; R3 is selected from phenyl, phenyl mono-substituted and phenyl di-substituted in positions 3 and 4; the substituents of the phenyl of R2 and R3 selected from halogen, (C1-C4)-alkyl and (C1-C4)-alkoxyl and R4 is selected from hydrogen, alkyl allyl and homoallyl, they are useful for the treatment of mycobacterial infections, in particular for the treatment of infections produced by Mycobacterium tuberculosis, Mycobacterium avium-intracellulare complex or Mycobacterium kansasii.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.